HomeProductsBioactive CompoundsMAPK/ERK Pathwayp38 MAPKSgx-523
Chemical structure of CAS 1022150-57-7

Sgx-523

CAS No.1022150-57-7
MDL No.MFCD16660190
MFC18H13N7S
MW359.40
InChI KeyBCZUAADEACICHN-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

SGX-523 is a triazolopyridazine, specifically 6-(1-methylpyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazine-3-thiol with the thiol hydrogen replaced by a quinolin-6-yl group. It functions as a c-Met tyrosine kinase inhibitor and a nephrotoxic agent. It belongs to quinolines, pyrazoles, biaryls, and aryl sulfides.

CAS No.1022150-57-7
Product NameSgx-523

Biological Targets

MET

Associated Conditions

cancer
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Comprehensive analysis of kinase inhibitor selectivity.

Nature biotechnology • Vol. 29, Issue 11 • 2011
PMID: 22037378DOI: 10.1038/nbt.1990

MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.

Cancer research • Vol. 70, Issue 17 • 2010
PMID: 20643778DOI: 10.1158/0008-5472.CAN-10-0898

Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications.

Drug metabolism and disposition: the biological fate of chemicals • Vol. 38, Issue 8 • 2010
PMID: 20421447DOI: 10.1124/dmd.110.032375

An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Anti-cancer agents in medicinal chemistry • Vol. 10, Issue 1 • 2010
PMID: 20015006PMC: PMC3278215DOI: 10.2174/1871520611009010028

Documentation